Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Studies from Novartis yield new data on angiogenesis
October 2nd, 2008
According to a study from Basel, Switzerland, "Dysregulated angiogenesis and high tumor vasculature permeability, two vascular endothelial growth factor (VEGF)mediated processes and hallmarks of human tumors, are in part phosphatidylinositol 3-kinase (PI3K) dependent. NVP-BEZ235, a dual PI3K/mammalian target of rapamycin (mTOR) inhibitor, was found to potently inhibit VEGF-induced cell proliferation and survival in vitro and VEGF-induced angiogenesis in vivo as shown with s.c. VEGF-impregnated agar chambers." "Moreover, the compound strongly inhibited micro-vessel permeability both in normal tissue and in BN472 mammary carcinoma grown orthotopically in syngeneic rats....
Source: Women's Health Weekly (2008-10-02)
|
